PILOPINE HS
LOE ApproachingNDAOPHTHALMICGEL
Approved
Oct 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PILOPINE HS is a topical ophthalmic gel formulation approved by the FDA in 1984 for eye care indications. The product is a small-molecule agent delivered directly to the eye via gel dosage form. Specific mechanism of action and therapeutic indications are not publicly detailed in available records.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a contracting commercial footprint and likely cost-conscious repositioning or harvest strategy by Alcon.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and an approaching LOE, PILOPINE HS represents a stable but declining career opportunity at Alcon. Professionals working on this product should expect focus on cost management, generic defense, and niche indication retention rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on PILOPINE HS at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.